TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit

Cancer Cell. 2014 Dec 8;26(6):785-787. doi: 10.1016/j.ccell.2014.11.016.


Combination therapies are becoming a focal point in cancer immunotherapy. In this issue of Cancer Cell, Johnston and colleagues identify the TIGIT/CD226 pathway, which provides significant interest for combination with PD-1 pathway blockade to improve anticancer CD8(+) T cell responses, because it acts by a novel mechanism to regulate CD8(+) T cell functions within the tumor microenvironment.

Publication types

  • Comment

MeSH terms

  • Animals
  • Antigens, Differentiation, T-Lymphocyte / metabolism*
  • CD8-Positive T-Lymphocytes / immunology*
  • Humans
  • Lymphocytic Choriomeningitis / immunology*
  • Neoplasms / immunology*
  • Receptors, Immunologic / metabolism*


  • Antigens, Differentiation, T-Lymphocyte
  • CD226 antigen
  • Receptors, Immunologic